Last updated 2026-07-27
- Went public on NASDAQ (PYPD), Jun 2020
- Raised $60M IPO, Jun 2020
- Raised $50M Series F, Aug 2019
Total raised
$187.5M
Last: B Round 2025-08
Stage
Public
Founded
2008
Headcount
76
HQ
Petah Tikva, Israel
Sector
Health Tech & Life Sciences
About
PolyPid is a late-stage biopharmaceutical company focused on improving surgical outcomes through its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. This technology enables the precise, controlled, and prolonged release of therapeutics, delivering drugs at optimal rates over extended durations. The company's lead product candidate, D-PLEX100, is in a phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. Additionally, PolyPid is developing OncoPLEX, which is in preclinical testing for treating solid tumors, including glioblastomas.
Funding history · 10 rounds · $187.5M total
2025-11
Follow-on PO
$15.0M
2023-05
Follow-on PO
$8.7M
2020-06
IPO
$60.0M
2019-08
F Round
$50.0M
2018-10
E Round
$15.0M
2016-10
Debt Financing
$5.3M
2016-01
C Round
$8.1M
★ Shavit Capital Fund★ Aurum Ventures M.K.I
2016-01
D Round
$22.0M
★ Shavit Capital FundChaim HurvitzAurum Ventures M.K.I
2011-12
B Round
$2.0M
2009-12
A Round
$1.4M
Headcount over time
From 60 (2018-09) to 75 (2026-03) · +15 (+25%) · 53 points · source: Finder history + radar grounding
Q&A
- What is PolyPid's primary focus?
- PolyPid is a late-stage biopharmaceutical company focused on improving surgical outcomes through its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology, which enables the precise, controlled, and prolonged release of therapeutics.
- What is PolyPid's lead product candidate and its current development stage?
- PolyPid's lead product candidate is D-PLEX100, which is in a phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections.
- When did PolyPid become a public company?
- PolyPid became public on NASDAQ in June 2020.
- What was the amount raised in PolyPid's Initial Public Offering in June 2020?
- PolyPid raised $60,000,000 in its Public Offering in June 2020.
- What was the most recent public offering amount for PolyPid?
- PolyPid's most recent public offering was in November 2025, raising $15,000,000.
- What is the status of PolyPid's D-PLEX100 SHIELD II trial as of March 2025?
- In March 2025, PolyPid announced the successful completion of enrollment in its Phase 3 SHIELD II trial of D-PLEX₁₀₀ for the prevention of abdominal colorectal surgical site infections.
- What was a significant development for PolyPid in June 2025 regarding its SHIELD II trial?
- In June 2025, PolyPid announced positive topline results from its Phase 3 SHIELD II trial, where D-PLEX₁₀₀ demonstrated a significant reduction in surgical site infections and successfully met its primary and all key secondary endpoints.
- What new delivery platform did PolyPid unveil in July 2025?
- In July 2025, PolyPid unveiled a long-acting GLP-1 Receptor Agonists Delivery Platform, targeting the diabetes and weight loss market.
- What regulatory milestone did PolyPid achieve in June 2026?
- In June 2026, PolyPid completed its New Drug Application (NDA) submission to the FDA for D-PLEX₁₀₀.
Team · 6
Noam Emanuel
Founder · Founder
CFO
Chief Commercial Officer
Chief Operating Officer - US
Executive Vice President R&D, Clinical and Regulatory Affairs
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2CB2B2C
Highlights
1 PatentsVerified
Tags
orthopedicsdentaldrug-deliverypharma-companiessustained-releasetherapeuticspain-reliefcancerbiopharmaceuticalsurgeons
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | polypid.com |
|---|---|
| linkedin.com/company/3835371 | |
| YouTube | youtube.com/channel/UCg4GYf435RD4QyLQUuhJc7g |
Identifiers & details
| Founded | 2008-2 |
|---|---|
| Employees (exact) | 76 |
| Market cap | $72.2M |
| Status reason | Public on NASDAQ on Jun 2020; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| Initial Public Offering | 2020-06 | NASDAQ | PYPD | $69.0M |
| Public Offering | 2023-03 | NASDAQ | PYPD | $6.2M |
Radar intelligence
Patents
| EPO | 13 |
|---|
Publications (Crossref)
| Works | 8 |
|---|
Web history (Wayback)
| Domain | polypid.com |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514105923 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 2008-02-24 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2021 |
| Active charges / liens | 0 |
| Registry events | 3 — people (3) |
| Registered address | הסיבים 18 פתח תקווה |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-15 | עדכון דירקטורים-הוספת דירקטור |
| 2026-06-15 | עדכון דירקטורים-הסרת דירקטור |
| 2026-06-14 | עדכון בעלי תפקידים |